CYDUCT DIAGNOSTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.305 USD | -12.86% |
|
-.--% | -40.20% |
| 04-02 | CYduct Diagnostics, Inc. Announces Positive Study Results for Biomarker Combinations in the Assessment of Breast Cancer | CI |
| 2021 | CYduct Diagnostics, Inc. announced a financing transaction | CI |
Sales per Business
| USD in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Technology, Applications, Medical Devices and Procedural Techniques
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +26.88% |
Sales per region
| USD in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +26.88% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Dominick Gatto
CEO | Chief Executive Officer | 63 | 17-06-14 |
Claus Madsen
DFI | Director of Finance/CFO | - | - |
Michael Stewart
COO | Chief Operating Officer | 66 | - |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Stewart
COO | Chief Operating Officer | 66 | - |
Dominick Gatto
CEO | Chief Executive Officer | 63 | 17-06-14 |
Company contact information
CYduct Diagnostics, Inc.
1698 Post Road East Suite 1A
06880, Westport
+888-545-9112
http://www.cyductdx.com
Sector
This company's sector is not yet available
- Stock Market
- Equities
- CYDX Stock
- Company CYduct Diagnostics, Inc.
